Efficacy and safety of 2-hour urokinase regime in acute pulmonary embolism: A randomized controlled trial

Respiratory Research

Volumn 10, Issue , 2009, Pages

  Wang, Chen ^a   Zhai, Zhenguo ^a   Yang, Yuanhua ^a   Yuan, Yadong ^b   Cheng, Zhaozhong ^c   Liang, Lirong ^a   Dai, Huaping ^a   Huang, Kewu ^a   Lu, Weixuan ^d   Zhang, Zhonghe ^e   Cheng, Xiansheng ^f   Shen, Ying H ^g  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c The Affiliated Hospital of Medical College of Qingdao   (China)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^e DALIAN MEDICAL UNIVERSITY   (China)

^f FUWAI HOSPITAL   (China)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE; WARFARIN; FIBRINOLYTIC AGENT;

ACUTE DISEASE; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART FUNCTION; HUMAN; LUNG EMBOLISM; LUNG PERFUSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

CHINA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; TREATMENT OUTCOME; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77149120492     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-10-128     Document Type: Article

References (31)

1. Cella G, Palla A, Sasahara AA. Controversies of different regimens of thrombolytic therapy in acute pulmonary embolism. Semin Thromb Hemost 1987, 13:163-70. 10.1055/s-2007-1003488, 3306927.
2. Gupta S, Gupta BM. Acute pulmonary embolism advances in treatment. J Assoc Physicians India 2008, 56:185-91.
3. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2008, 133:454S-545S. 8, 10.1378/chest.08-0658, 18574272.
4. Kuthan F. Urokinase pulmonary embolism trial. JAMA 1971, 215:1503. 10.1001/jama.215.9.1503, 5107636.
5. Wenger NK. Pulmonary embolism and the urokinase pulmonary embolism trial. J Med Assoc Gay 1970, 59:161-2.
6. Wang F, Wang C, Wang T, Pang BS, Wu YB, Yang YH, Li C, Zhang HY, Weng XZ. [Experimental study of the thrombolytic effects in a canine model of pulmonary thromboembolism induced by autologous radioactive blood clots]. Zhonghua Jie He He Hu Xi Za Zhi 2004, 27:93-6.
7. Tebbe U, Graf A, Kamke W, Zahn R, Forycki F, Kratzsch G, Berg G. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999, 138:39-44. 10.1016/S0002-8703(99)70243-7, 10385761.
8. Fava M, Loyola S, Flores P, Huete I. Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism. J Vasc Interv Radiol 1997, 8:261-6. 10.1016/S1051-0443(97)70552-9, 9083994.
9. Ashton RW, Daniels CE, Ryu JH. Thrombolytic therapy in patients with submassive pulmonary embolism. N Engl J Med 2003, 348:357-9. 10.1056/NEJM200301233480416, 12540653.
10. Kreit JW. The impact of right ventricular dysfunction on the prognosis and therapy of normotensive patients with pulmonary embolism. Chest 2004, 125:1539-45. 10.1378/chest.125.4.1539, 15078772.
11. Zhu L, Yang YH, Wu YF, Zhai ZG, Wang C. Value of transthoracic echocardiography combined with cardiac troponin I in risk stratification in acute pulmonary thromboembolism. Chin Med J (Engl) 2007, 120:17-21.
12. Stein PD, Terrin ML, Gottschalk A, Alavi A, Henry JW. Value of ventilation/perfusion scans versus perfusion scans alone in acute pulmonary embolism. Am J Cardiol 1992, 69:1239-41. 10.1016/0002-9149(92)90944-T, 1575198.
13. Meyer G, Collignon MA, Guinet F, Jeffrey AA, Barritault L, Sors H. Comparison of perfusion lung scanning and angiography in the estimation of vascular obstruction in acute pulmonary embolism. Eur J Nucl Med 1990, 17:315-9. 10.1007/BF01268022, 2126770.
14. Qanadli SD, El M, Vieillard-Baron A, Joseph T, Mesurolle B, Oliva VL, Barré O, Bruckert F, Dubourg O, Lacombe P. New CT index to quantify arterial obstruction in pulmonary embolism: comparison with angiographic index and echocardiography. AJR Am J Roentgenol 2001, 176:1415-20.
15. Meer RW, Pattynama PM, van Strijen MJ, Berg-Huijsmans AA, Hartmann IJ, Putter H, de Roos A, Huisman MV. Right ventricular dysfunction and pulmonary obstruction index at helical CT: prediction of clinical outcome during 3-month follow-up in patients with acute pulmonary embolism. Radiology 2005, 235:798-803. 10.1148/radiol.2353040593, 15845793.
16. Sasahra AA, Bell WR, Simon TL, Stengle JM, Sherry S. The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study. Thromb Diath Haemorrh 1975, 33:464-76.
17. Walsh PN, Stengle JM, Sherry S. The urokinase-pulmonary embolism trial. Circulation 1969, 39:153-6.
18. Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, Lesaffre E, Vanhove P, Verstraete M. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. J Am Coll Cardiol 1992, 19:239-45.
19. Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GV, Dawley D, Nagel JS, Meyerovitz M, Kim D, Vaughan DE, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988, 2:293-8. 10.1016/S0140-6736(88)92354-9, 2899718.
20. Cheng X, He J, Gao M, Chen G, Li S, Zhang Z, Zhao M, Zhou S, Zhao J, Cheng L, Zhang Z, Chen Y, Xiong C. [Multicenter clinical trial on the efficacy of thrombolytic therapy with urokinase and/or anticoagulant with low molecular weight heparin in acute pulmonary embolism]. Zhonghua Nei Ke Za Zhi 2002, 41:6-10.
21. Miller GA, Sutton GC. Acute massive pulmonary embolism. Clinical and haemodynamic findings in 23 patients studied by cardiac catheterization and pulmonary arteriography. Br Heart J 1970, 32:518-23. 10.1136/hrt.32.4.518, 487364, 5433313.
22. Tow DE, Simon AL. Comparison of lung scanning and pulmonary angiography in the detection and follow-up of pulmonary embolism: the Urokinase-Pulmonary Embolism Trial experience. Prog Cardiovasc Dis 1975, 17:239-45. 10.1016/S0033-0620(75)80015-6, 1114271.
23. Lim KE, Chan CY, Chu PH, Hsu YY, Hsu WC. Right ventricular dysfunction secondary to acute massive pulmonary embolism detected by helical computed tomography pulmonary angiography. Clin Imaging 2005, 29:16-21. 10.1016/j.clinimag.2004.04.023, 15859013.
24. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002, 347:1143-50. 10.1056/NEJMoa021274, 12374874.
25. Ashton RW, Daniels CE, Ryu JH. Thrombolytic therapy in patients with submassive pulmonary embolism. N Engl J Med 2003, 348:357-9. 10.1056/NEJM200301233480416, 12540653.
26. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, Pruszczyk P, Bengel F, Brady AJ, Ferreira D, Janssens U, Klepetko W, Mayer E, Remy-Jardin M, Bassand JP, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Zamorano JL, Andreotti F, Ascherman M, Athanassopoulos G, De Sutter J, Fitzmaurice D, Forster T, Heras M, Jondeau G, Kjeldsen K, Knuuti J, Lang I, Lenzen M, Lopez-Sendon J, Nihoyannopoulos P, Perez L, Schwehr U, Torraca L, Vachiery JL, . Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008, 29:2276-315. 10.1093/eurheartj/ehn475, 18757870, Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology.
27. Kanter DS, Mikkola KM, Patel SR, Parker JA, Goldhaber SZ. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997, 111:1241-5. 10.1378/chest.111.5.1241, 9149576.
28. Terrin M, Goldhaber SZ, Thompson B. Selection of patients with acute pulmonary embolism for thrombolytic therapy. Thrombolysis in pulmonary embolism (TIPE) patient survey. The TIPE Investigators. Chest 1989, 95:279S-81S.
29. The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. The UKEP Study Research Group. Eur Heart J 1987, 8:2-10.
30. PEITHO Pulmonary Embolism Thrombolysis Study. , http://clinicaltrials.gov/ct2/show/NCT00639743
31. Meneveau N, Schiele F, Metz D, Valette B, Attali P, Vuillemenot A, Grollier G, Elaerts J, Mossard JM, Viel JF, Bassand JP. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998, 31:1057-63. 10.1016/S0735-1097(98)00068-0, 9562007.